COSCIENS Biopharma Inc. Deferred Tax Expense Income
COSCIENS Biopharma Inc. (CSCIF) reported Deferred Tax Expense Income of $3.48 million for the 12-month period ending 2018-12-31, per its 20-F filed 2020-03-31.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2020-03-31
- COSCIENS Biopharma Inc. deferred tax expense income for the quarter ending 2018-12-31 was $0.00.
- COSCIENS Biopharma Inc. deferred tax expense income for the quarter ending 2018-09-30 was $0.00.
| Period end | Deferred Tax Expense Income 3 month | Deferred Tax Expense Income 6 month | Deferred Tax Expense Income 9 month | Deferred Tax Expense Income 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2020-03-31 | $0.00 derived: sum of 2 quarters · filed 2020-03-31 | $3.48M 20-F · filed 2020-03-31 | |
| 2018-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2019-11-07 | $3.48M 6-K · filed 2019-11-07 | ||
| 2018-06-30 | $3.48M 6-K · filed 2019-08-13 | |||
| 2017-12-31 | -$3.48M 20-F · filed 2020-03-31 | |||
| 2016-12-31 | $0.00 20-F · filed 2019-04-01 | |||
| 2015-12-31 | $0.00 20-F · filed 2018-03-28 |